Replies to post #121734 on Anavex Life Sciences Corp (AVXL)

[blue finch]

Just remember that short 12 week rett. Trial could turn into a year after while the data is analyzed

Don’t get your hopes up for much

[F1ash]

If, just if, Anavex proves successful in the short 12 week Rett trial, which could be halted early based on efficacy, can you imagine what that will do to confidence among investors in their other indications.

"Scheduled to begin in 2017, the trial will be a randomized, double blind, placebo-controlled study of ANAVEX 2-73 in patients with Rett syndrome lasting up to 12 weeks."

Probably be difficult to end it early because they won't know who is receiving placebo or the drug until they unblind the trial.

And the following statement explains why I believe Anavex will/should tap LPC for every single dime possible before ever completing a trial for anything. Was institutional investment a good indication of potential success for them?


http://www.nasdaq.com/symbol/axon/institutional-holdings


"If the study had succeeded, shares might have soared as high as $100; as it is, they could trade down toward Axovant’s cash position of $3"

"If Axovant shares do crash dramatically, there could be an argument for buying them, based on the company's healthy cash position, Hung's track record, the potential for the company to buy other drugs, as well as an experimental drug for Parkinson's psychosis it is developing. "

https://www.forbes.com/sites/matthewherper/2017/09/26/axovant-raised-hundreds-of-millions-around-its-alzheimers-drug-it-just-failed/?c=0&s=trending#bbafd7813657

[nidan7500]

can you imagine what that will do to confidence among investors in their other indications.

IMO, that has been his plan. It is all based on validation of the thesis on CNS Homeostasis restoration/regeneration. When that is proven then all options are on the table, IMO. Completely different thought process for trials/see RWE.